Glenmark Pharmaceuticals Gains US FDA Approval for 100 mg Progesterone Vaginal Inserts

Glenmark Pharmaceuticals has secured final approval from the United States Food and Drug Administration (US FDA) for its Progesterone Vaginal Inserts, 100 mg. The product has been deemed bioequivalent to an already approved reference listed drug by the regulatory agency. This development marks a significant milestone for Glenmark in expanding its portfolio of pharmaceutical products in the U.S. market.

The Progesterone Vaginal Inserts are designed for specific medical applications, and their approval follows rigorous evaluation by the US FDA to ensure safety, efficacy, and quality standards. The inserts are intended to provide therapeutic benefits comparable to the reference product, as confirmed through bioequivalence studies. Glenmark’s receipt of this approval enables the company to proceed with manufacturing and distribution of the product within the United States, further strengthening its presence in one of the world’s largest pharmaceutical markets.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI